HUTCHMED to Showcase Novel Cancer Therapies at AACR 2026
Event summary
- HUTCHMED will present preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate (ATTC), at the AACR Annual Meeting 2026.
- Updated results from a Phase Ib/II trial of surufatinib plus sintilimab and capecitabine for metastatic small bowel adenocarcinoma and appendiceal carcinoma will be shared.
- Exploratory Phase II study results for surufatinib combined with gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma will be presented.
- HMPL-A580 demonstrated robust anti-tumor effects in preclinical models, with strong selectivity and favorable pharmacokinetic properties.
The big picture
HUTCHMED's presentation at AACR 2026 highlights its focus on next-generation precision oncology, combining targeted therapies to achieve synergistic anti-tumor activity. The company's ATTC platform aims to overcome challenges faced by existing PAM-targeted drugs, positioning it in a competitive oncology market. The strategic emphasis on leveraging partnerships to accelerate global development underscores HUTCHMED's ambition to address large unmet needs in cancer treatment.
What we're watching
- Clinical Validation
- Whether HMPL-A580's preclinical promise translates into clinical efficacy and safety in human trials.
- Market Differentiation
- How HUTCHMED's ATTC platform will compete against traditional antibody-drug conjugates in the oncology market.
- Regulatory Pathway
- The pace at which surufatinib and HMPL-A580 advance through regulatory approvals in key markets.
Related topics